Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology ForumPRNewsWire • 04/10/24
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary SessionPRNewsWire • 04/08/24
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)PRNewsWire • 04/05/24
Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid LeukemiaPRNewsWire • 03/28/24
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute LeukemiaPRNewsWire • 03/26/24
Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business UpdatePRNewsWire • 02/27/24
Syndax (SNDX) is on the Move, Here's Why the Trend Could be SustainableZacks Investment Research • 02/26/24
Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024PRNewsWire • 02/20/24
Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional SharesPRNewsWire • 12/19/23
Syndax Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual MeetingPRNewsWire • 12/12/23
Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination TrialsPRNewsWire • 12/11/23
Syndax to Host Investor Event to Discuss Axatilimab and Revumenib Data Updates at 65th ASH Annual MeetingPRNewsWire • 12/04/23
Syndax Announces Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Selected as Late-Breaking Presentation at the 65th ASH Annual MeetingPRNewsWire • 11/21/23
Syndax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Business UpdatePRNewsWire • 11/02/23
Syndax Announces Updated Data Supporting Impressive Clinical Profile of Revumenib in Genetically-Defined Acute Leukemias to Be Presented at the 65th ASH Annual MeetingPRNewsWire • 11/02/23